Rendas-Baum, Regina
Lin, Xiaochen
Kosinski, Mark
Bjorner, Jakob Bue
Bracher, Marguerite G.
Chen, Wen-Hung
Funding for this research was provided by:
GSK (GSK)
Article History
Received: 11 May 2023
Accepted: 3 January 2024
First Online: 22 January 2024
Declarations
:
: Ethical approval was not required for this post-hoc secondary analysis of existing Phase 2 clinical trial data. However, patients provided consent for such secondary data analyses in the informed consent forms for the BAROQUE and RENAISSANCE clinical trials.
: Not applicable.
: RR-B, MK, and JBB are employees of QualityMetric Inc, who received consulting fees for the conduct of this analysis but not for manuscript development. XL was an employee of QualityMetric Inc at the time of the study and is currently an employee of, and holds stocks/shares in, Biogen. MGB and W-HC are employees of, and holds stocks/shares in, GSK.